Inhibition of metastasis by cicaprost in rats with established SMT2A mammary carcinoma growth

Cancer Detect Prev. 1997;21(1):44-50.

Abstract

Cicaprost, a stable prostacyclin analog has been shown to be antimetastatically active in a series of metastasizing rodent tumors. Whereas starting treatment with Cicaprost on the day of tumor implantation was a characteristic feature of our previous investigations, the present study focused on the antimetastatic potency of Cicaprost in animals with established tumor growth. We have previously reported that, in Wistar-Furth rats bearing subcutaneously implanted SMT2A mammary carcinoma, Cicaprost in daily oral doses of 0.1 to 1.0 mg/kg given from the day of tumor implantation to the end of the experiment led to a strong decrease in the number of lung metastases. The 1.0 mg/kg doses reduced the number of lung metastases by about 95% compared with the control. In the present study, we have examined the effect of delaying the start of treatment in animals with established tumor growth, Cicaprost in daily oral doses of 0.1 mg/kg given from Day 10 until Day 32 reduced the number of lung metastases by about 80% compared with the control. In contrast, surgical removal of palpable primary tumors had no effect on lung metastasis. We conclude that Cicaprost exhibits strong antimetastatic activity in the SMT2A rat mammary carcinoma model and interferes not only with mechanisms of tumor cell-blood cell interaction, tumor cell adhesion, and extravasation, but also with steps following extravasation.

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Cell Division / drug effects
  • Epoprostenol / analogs & derivatives*
  • Epoprostenol / therapeutic use
  • Female
  • Lung Neoplasms / prevention & control*
  • Lung Neoplasms / secondary*
  • Mammary Neoplasms, Experimental / pathology*
  • Mammary Neoplasms, Experimental / prevention & control*
  • Neoplasm Metastasis
  • Neoplasm Transplantation
  • Rats
  • Rats, Inbred WF

Substances

  • Antineoplastic Agents
  • Epoprostenol
  • cicaprost